Vitrafy Life Sciences (ASX:VFY)
ASX announcement history & article coverage
Transparent by design.
Announcments by Vitrafy Life Sciences (ASX:VFY) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
2026 Notice of Annual General Meeting
Investor Roadshow Presentation
Change to CEO Remuneration and Employment Terms
Vitrafy enters partnership with Versiti Blood Health
Vitrafy partners with Versiti to advance cryopreserved platelet technology and U.S. device listing
Vitrafy enters U.S. Cell & Gene Therapy Market
Vitrafy Enters U.S. Cell and Gene Therapy Market with Charter Medical Agreement
FY26 Corporate Governance Statement
FY26 Appendix 4G
FY26 Full Year Results Presentation
Vitrafy Life Sciences delivers FY26 milestones with strong revenue growth and U.S. market expansion underway
FY26 Appendix 4E and Annual Report
Vitrafy reports revenue growth, reduced loss, US military validation, and $32m capital raise
Vitrafy FY26 Investor Briefing
Q4 FY26 Quarterly Activities Report and Appendix 4C
Vitrafy reports strong Q4 results, $32m capital raise, advances platelet cryopreservation and U.S. expansion
Vitrafy enters a partnership with Hoxworth Blood Center
Vitrafy partners with Hoxworth Blood Center to tackle US red blood cell preservation crisis
Application for quotation of securities - VFY